Skip to content
★ Sign in to follow
EC

Erez Chimovits

Executive
Upstream Bio, Inc.LogicBio Therapeutics, Inc.Braveheart Bio, Inc.ADARx Pharmaceuticals, Inc.Adicet Bio, Inc.BiomX Inc.Eledon Pharmaceuticals, Inc.
Insider activity · 24 months1 buy0 salesCumulative net flow
Total declarations
29
Companies
7
▲ Purchases (17 ops.)
€57.9M
▼ Sales (0 ops.)
—

Latest filing published 30 Sept 2026 for ADARx Pharmaceuticals, Inc., €918k.

Filing timeline

BuySale
Erez Chimovits

Insider track record

Disclosed buys
17
Disclosed sells
0
Signal history

Closed purchases

Market purchases
17

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Since each purchase

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Erez Chimovits: trading record in brief

Erez Chimovits discloses dealings in 7 companies, chiefly BiomX Inc., ADARx Pharmaceuticals, Inc. and LogicBio Therapeutics, Inc. Between 23 October 2018 and 28 September 2026, the trades on record add up to 29 filings.

The open-market record is one-sided, with 17 purchases worth €57.9M and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 4 share grants. 2026 to date brings 3 purchases and no sales.

Half of the purchases are above €1.5M and half below. Clusters matter here: 15 out of 15 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

Most recently, on 30 September 2026, the filings show an open-market purchase worth €918k in ADARx Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Companies and markets linked to Erez Chimovits

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations16 total
  • ▲
    DirectorExecutivesADARx Pharmaceuticals, Inc.
    1M USD37SEC
    61,516 shares@ US$17.00100.0% of flowCommon StockSEC:0000947871-26-000912:4
    Canonical exit: 27 Dec 2026 (T+90)
  • ●
    DirectorExecutivesADARx Pharmaceuticals, Inc.
    0SEC
    513,067 sharesCommon StockSEC:0000947871-26-000912:2
  • ●
    DirectorExecutivesADARx Pharmaceuticals, Inc.
    0SEC
    256,448 sharesCommon StockSEC:0000947871-26-000912:3
  • ●
    DirectorExecutivesADARx Pharmaceuticals, Inc.
    0SEC
    1,333,975 sharesCommon StockSEC:0000947871-26-000912:1
  • ●
    DirectorExecutivesADARx Pharmaceuticals, Inc.
    0SEC
    7,127,019 sharesCommon StockSEC:0000947871-26-000912:0
  • ●
    DirectorExecutivesBraveheart Bio, Inc.
    0SEC
    9,132,420 sharesCommon StockSEC:0000947871-26-000783:0
  • ▲
    DirectorExecutivesBraveheart Bio, Inc.

    Same trade as the filing by Orbimed Advisors LLC, counted once

    30M USD59SEC
    1,666,667 shares@ US$18.001.60% mcap85.9% of flowCommon StockSEC:0000947871-26-000783:1
    Canonical exit: 5 Nov 2026 (T+90)
  • ▲
    DirectorExecutivesBraveheart Bio, Inc.

    Same trade as the filing by Orbimed Advisors LLC, counted once

    5M USD47SEC
    273,333 shares@ US$18.000.26% mcap14.1% of flowCommon StockSEC:0000947871-26-000783:2
    Canonical exit: 5 Nov 2026 (T+90)
  • ▲
    DirectorExecutivesUpstream Bio, Inc.

    Same trade as the filing by Orbimed Advisors LLC, counted once

    11M USD34SEC
    660,000 shares@ US$17.0080.0% of flowCommon StockSEC:0000947871-24-000807:3
    Canonical exit: 13 Jan 2025 (T+90)
  • ▲
    DirectorExecutivesUpstream Bio, Inc.

    Same trade as the filing by Orbimed Advisors LLC, counted once

    3M USD28SEC
    165,000 shares@ US$17.0020.0% of flowCommon StockSEC:0000947871-24-000807:1
    Canonical exit: 13 Jan 2025 (T+90)
  • ●
    DirectorExecutivesUpstream Bio, Inc.
    0SEC
    2,887,833 sharesCommon StockSEC:0000947871-24-000807:2
  • ●
    DirectorExecutivesUpstream Bio, Inc.
    0SEC
    721,956 sharesCommon StockSEC:0000947871-24-000807:0
  • ◆
    DirectorExecutivesAdicet Bio, Inc.
    5M USD19SEC
    420,299 shares@ US$13.0080.2% of flowCommon StockSEC:0000947871-21-000242:0
  • ◆
    DirectorExecutivesAdicet Bio, Inc.
    1M USD13SEC
    104,050 shares@ US$13.0019.8% of flowCommon StockSEC:0000947871-21-000242:1
  • ▲
    DirectorExecutivesLogicBio Therapeutics, Inc.
    3M USD27SEC
    545,974 shares@ US$6.0036.9% of flowCommon StockSEC:0000947871-20-000776:0
    Canonical exit: 30 Dec 2020 (T+90)
  • ▲
    DirectorExecutivesLogicBio Therapeutics, Inc.
    4M USD27SEC
    639,212 shares@ US$6.0043.1% of flowCommon StockSEC:0000947871-20-000776:1
    Canonical exit: 30 Dec 2020 (T+90)
  • ▲
    DirectorExecutivesLogicBio Therapeutics, Inc.
    2M USD25SEC
    296,296 shares@ US$6.0020.0% of flowCommon StockSEC:0000947871-20-000776:2
    Canonical exit: 30 Dec 2020 (T+90)
  • ◆
    DirectorExecutivesAdicet Bio, Inc.
    0SEC
    292,607 sharesCommon StockSEC:0000947871-20-000740:1
  • ◆
    DirectorExecutivesAdicet Bio, Inc.
    0SEC
    902,885 sharesCommon StockSEC:0000947871-20-000740:0
  • ▲
    DirectorExecutivesBiomX Inc.

    Same trade as the filing by OrbiMed Israel BioFund GP Limited Partnership, counted once

    4,465 USD32SEC
    500 shares@ US$8.932.2% of flowCommon Stock, $0.001 par valueSEC:0000947871-19-000982:0
    Canonical exit: 17 Mar 2020 (T+90)
  • ▲
    DirectorExecutivesBiomX Inc.

    Same trade as the filing by OrbiMed Israel BioFund GP Limited Partnership, counted once

    31,150 USD34SEC
    3,500 shares@ US$8.9015.6% of flowCommon Stock, $0.001 par valueSEC:0000947871-19-000982:1
    Canonical exit: 18 Mar 2020 (T+90)
  • ▲
    DirectorExecutivesBiomX Inc.

    Same trade as the filing by OrbiMed Israel BioFund GP Limited Partnership, counted once

    29,750 USD33SEC
    3,400 shares@ US$8.7515.0% of flowCommon Stock, $0.001 par valueSEC:0000947871-19-000962:0
    Canonical exit: 9 Mar 2020 (T+90)
  • ▲
    DirectorExecutivesBiomX Inc.

    Same trade as the filing by OrbiMed Israel BioFund GP Limited Partnership, counted once

    48,168 USD34SEC
    5,400 shares@ US$8.9224.2% of flowCommon Stock, $0.001 par valueSEC:0000947871-19-000962:1
    Canonical exit: 10 Mar 2020 (T+90)
  • ▲
    DirectorExecutivesBiomX Inc.

    Same trade as the filing by OrbiMed Israel BioFund GP Limited Partnership, counted once

    27,166 USD27SEC
    3,400 shares@ US$7.9913.6% of flowCommon Stock, $0.001 par valueSEC:0000947871-19-000947:0
    Canonical exit: 4 Mar 2020 (T+90)
  • ▲
    DirectorExecutivesBiomX Inc.

    Same trade as the filing by OrbiMed Israel BioFund GP Limited Partnership, counted once

    6,400 USD28SEC
    800 shares@ US$8.003.2% of flowCommon Stock, $0.001 par valueSEC:0000947871-19-000947:1
    Canonical exit: 5 Mar 2020 (T+90)

25 of 16 declarations